FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Drew Armstrong

Executive Editor

The Federal Trade Commission said that it is suing the three major US pharmacy benefit managers over their role in the insulin market, claiming that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Biotech VC firm outlines plans for $100M fund

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA approves Zevra’s rare disease drug after resubmission

FDA OKs the first-ever self-administered vaccine, for flu

Breaking down silos with a new quantitative approach to drug development

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

Executive Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost